Latest Blog Posts Tagged "Research News"
June 23, 2017
Researchers have developed a tool to predict cognitive decline in PD for use in designing clinical studies. The team analyzed data from multiple studies including PPMI.
June 22, 2017
MJFF-funded researchers published on a connection between the key Parkinson's protein alpha-synuclein and the immune system. This finding may point to a new way to stop or slow disease.
May 31, 2017
People respond differently to the same medicine, which is why researchers are addressing this challenge through "precision medicine."
May 25, 2017
The 13th International Conference on Alzheimer's and Parkinson's Diseases and Related Neurological Disorders took place in March 2017, with speakers including MJFF's Jamie Eberling, PhD.
May 17, 2017
Analysis of data from the MJFF-sponsored Parkinson's Progression Markers Initiative gives window into how and why cognitive problems develop in PD
May 08, 2017
In his latest blog post for the Journal of Parkinson's Disease, science journalist and person with Parkinson's Jon Palfreman introduces us to Personalized Parkinson Project.
Uncovering the Promise of c-Abl as a Therapeutic Target: Testing Available Treatments and Supporting New Therapies
March 15, 2017
MJFF CEO Todd Sherer, PhD, discusses varied work happening around c-Abl inhibitors, an emerging therapeutic target that has shown early promise as a potential disease-modifying therapy.
February 14, 2017
A new study suggests that evaluating levels of a certain protein in the blood may help distinguish Parkinson's from certain atypical parkinsonisms.
February 14, 2017
This study is a major step for PD research as it is the first drug trial where one's genetic information determines eligibility and is testing a potential therapy to slow or stop disease progression.
February 10, 2017
MJFF funded early research of this novel drug candidate, mGluR4, helping remove financial and other barriers to advance its testing.